Page last updated: 2024-12-06

5-iminodaunorubicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

A synthetic analog of daunorubicin, an anthracycline antibiotic, with potent cytotoxic activity against a range of cancer cell lines. It exhibits a mechanism of action similar to daunorubicin, intercalating into DNA and inhibiting topoisomerase II activity. 5-iminodaunorubicin has been investigated in preclinical and clinical trials as a potential anticancer agent, particularly for the treatment of leukemia and solid tumors, though it has not yet achieved widespread clinical use.'

5-iminodaunorubicin: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72400
CHEMBL ID3304020
MeSH IDM0071048

Synonyms (23)

Synonym
brn 4069837
ccris 5676
5(8h)-naphthacenone, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-12-imino-1-methoxy-, (8s-cis)-
5-iminodaunomycin
(8s,10s)-8-acetyl-10-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,8,11-trihydroxy-12-imino-1-methoxy-9,10-dihydro-7h-tetracen-5-one
5-iminodaunorubicin
5(8h)-naphthacenone der.
5-id
(8s-cis)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-(hexopyranosyl)oxy]-7,9,10,12-tetrahydro-6,8,11-trihydroxy-12-imino-1-methoxy-5(8h)-naphthacenone
72983-78-9
p910685s6g ,
unii-p910685s6g
CHEMBL3304020
5(8h)-naphthacenone, 8-acetyl-10-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-12-imino-1-methoxy-, (8s,10s)-
(8s,10s)-8-acetyl-10-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-12-imino-1-methoxy-5(8h)-naphthacenone
Q27286385
MS-29746
(8s,10s)-8-acetyl-10-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,8,11-trihydroxy-12-imino-1-methoxy-9,10-dihydro-7h-tetracen-5-one
nsc833900
nsc-833900
HY-138645
CS-0159974
PD157779

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"7 X 10(-7) M for 50% cell survival) which were not toxic if administered in the dark."( Photocytotoxicity of anthracyclines upon laser excitation in their long-wavelength absorption bands.
Andreoni, A; Colasanti, A; Malatesta, V; Roberti, G, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (77.78)18.7374
1990's5 (13.89)18.2507
2000's3 (8.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.38 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.02 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (97.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]